Dexcom Inc (DXCM) · Oct 29, 2026 · Earnings
Beat — Non-GAAP diluted EPS $0.73 vs ~$0.675 consensus
Dexcom earnings beat Q3 expectations on revenue and adjusted EPS, while higher 2026 guidance and a new $1B buyback reinforce the improving story.
Dexcom is in the middle of expanding its continuous glucose monitoring franchise beyond its traditional base, while shifting customers onto the longer-wear G7 15 Day platform and broadening the Type 2 diabetes opportunity. That broader expansion was already part of the standing story, but this quarter adds better-than-expected execution and another upward reset to the outlook. Dexcom’s prior quarter guidance called for 2026 revenue of $5.18–$5.25 billion and non-GAAP operating margin of approximately 23.5%–24%.
The quarter cleared the market’s bar. Revenue was $1.3445 billion versus a published consensus of roughly $1.33 billion, while non-GAAP diluted EPS was $0.73 versus approximately $0.675. Revenue grew 11.2% year over year, and adjusted EPS rose nearly 20%, showing that the result was not just a top-line beat but also a margin-and-earnings delivery.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Income Statement) | $1,344.5M (+11.2%) | $1,209.3M | ~$1,330M |
| Non-GAAP diluted EPS (Non-GAAP EPS reconciliation) | $0.73 (+19.7%) | $0.61 | ~$0.675 |
| GAAP operating margin (Operating Income) | 24.3% (+420 bps) | 20.1% | |
| Non-GAAP operating margin (Non-GAAP reconciliation) | 25.3% (+270 bps) | 22.6% |
The quality of the beat improved. Operating income grew much faster than revenue, with GAAP operating margin reaching 24.3% and non-GAAP operating margin 25.3%. That is meaningful because Dexcom’s current business challenge is not simply finding demand; it is converting product expansion and manufacturing scale into durable profitability.
Management raised the full-year framework again. The release says Dexcom raised the midpoint of 2026 revenue guidance and increased full-year non-GAAP operating-margin and adjusted-EBITDA-margin guidance, while reiterating gross-margin guidance. The supplied filing extract does not include the revised numerical ranges, so the direction is clearly positive but the size of the reset cannot be measured precisely here. 〔0〕
The product expansion is gaining evidence, not just marketing support. Dexcom published the CONNECT randomized trial in the New England Journal of Medicine after the quarter and continued the U.S. rollout of G7 15 Day, with its first two international regulatory clearances. That supports the company’s push into non-insulin Type 2 diabetes and the transition of its installed base to a longer-wear product. 〔1〕
The $1 billion repurchase authorization adds a new capital-allocation signal. It gives Dexcom a sizeable way to return excess cash while the company still reports $1.82 billion of cash, cash equivalents and marketable securities and an undrawn revolving facility. The authorization is discretionary and does not require any purchases, so it is a commitment of capacity rather than an immediate reduction in share count.
Bottom line: This was more than an in-line quarter: Dexcom beat on revenue and adjusted EPS, expanded margins, raised its outlook again, and added a large buyback. The core G7 15 Day and broader-Type 2 strategy is moving from promise toward measurable execution, although the missing revised guidance figures limit precision on how large the upgrade was.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!